Bladder biopsy

PROCEDURE3 trials

Sponsors

Tengion, Insel Gruppe AG, University Hospital Bern, National Cancer Institute (NCI)

Conditions

Bladder DiseaseDisorder of the Lower Urinary TractUrinary Bladder Neoplasms

Phase 1

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

CompletedNCT03258593

National Cancer Institute (NCI)Urinary Bladder Neoplasms

Start: 2018-06-07End: 2022-10-17Updated: 2026-08-25

Unknown Phase

Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure

CompletedNCT00615043

TengionBladder Disease

Start: 2008-02-29End: 2008-12-31Updated: 2010-12-22

Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction

CompletedNCT02410876

Insel Gruppe AG, University Hospital BernDisorder of the Lower Urinary Tract

Start: 2015-06-30End: 2020-12-31Updated: 2021-04-29

Related Papers

MP16-20 FINAL RESULTS OF A PHASE I, SINGLE-ARM CLINICAL TRIAL OF THE COMBINATION OF DURVALUMAB AND VICINEUM IN BCG UNRESPONSIVE, HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS (NCT03258593)

The Journal of Urology2024-04-153 citations

PD48-09 A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (Q-TWIST) ANALYSIS OF SYSTEMIC THERAPY VERSUS STANDARD OF CARE INTRAVESICAL TREATMENT (BCG) IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS

The Journal of Urology2024-04-15

PD09-04 INTERIM ANALYSIS OF A PHASE I SINGLE-ARM STUDY OF THE COMBINATION OF DURVALUMAB (MEDI4736) AND VICINIUM (OPORTUZUMAB MONATOX, VB4-845) IN SUBJECTS WITH HIGH-GRADE NON-MUSCLE-INVASIVE BLADDER CANCER PREVIOUSLY TREATED WITH BACILLUS CALMETTE-GUERIN (BCG) (NCT03258593)

The Journal of Urology2021-08-045 citations